Facile and rapid detection of SARS-CoV-2 antibody based on a noncompetitive fluorescence polarization immunoassay in human serum samples.


Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
15 Oct 2021
Historique:
received: 07 04 2021
revised: 27 05 2021
accepted: 03 06 2021
pubmed: 16 6 2021
medline: 23 7 2021
entrez: 15 6 2021
Statut: ppublish

Résumé

Antibody detection methods for viral infections have received broad attention due to the COVID-19 pandemic. In addition, there remains an ever-increasing need to quantitatively evaluate the immune response to develop vaccines and treatments for COVID-19. Here, we report an analytical method for the rapid and quantitative detection of SARS-CoV-2 antibody in human serum by fluorescence polarization immunoassay (FPIA). A recombinant SARS-CoV-2 receptor binding domain (RBD) protein labeled with HiLyte Fluor 647 (F-RBD) was prepared and used for FPIA. When the anti-RBD antibody in human serum binds to F-RBD, the degree of polarization (P) increases by suppressing the rotational diffusion of F-RBD. The measurement procedure required only mixing a reagent containing F-RBD with serum sample and measuring the P value with a portable fluorescence polarization analyzer after 15 min incubation. We evaluated analytical performance of the developed FPIA system using 30 samples: 20 COVID-19 positive sera and 10 negative sera. The receiver operating characteristic curve drawn with the obtained results showed that this FPIA system had high accuracy for discriminating COVID-19 positive or negative serum (AUC = 0.965). The total measurement time was about 20 min, and the serum volume required for measurement was 0.25 μL. Therefore, we successfully developed the FPIA system that enables rapid and easy quantification of SARS-CoV-2 antibody. It is believed that our FPIA system will facilitate rapid on-site identification of infected persons and deepen understanding of the immune response to COVID-19.

Identifiants

pubmed: 34130087
pii: S0956-5663(21)00451-6
doi: 10.1016/j.bios.2021.113414
pmc: PMC8178067
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113414

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Talanta. 2021 Feb 1;223(Pt 1):121737
pubmed: 33303174
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Anal Bioanal Chem. 2021 Jul;413(18):4619-4623
pubmed: 33547481
Sens Actuators B Chem. 2020 Aug 1;316:128160
pubmed: 32322135
Analyst. 2020 Aug 7;145(15):5345-5352
pubmed: 32568341
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33483360
N Engl J Med. 2020 Dec 31;383(27):2684-2686
pubmed: 33326716
J Med Virol. 2021 Mar;93(3):1436-1442
pubmed: 32790181
Cell Mol Immunol. 2020 May;17(5):555-557
pubmed: 32235915
Eur J Intern Med. 2021 May;87:104-105
pubmed: 33581978
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Lab Chip. 2016 Feb 7;16(3):586-92
pubmed: 26753557
Virus Res. 2020 Oct 15;288:198114
pubmed: 32800805
Rev Med Virol. 2020 May;30(3):e2106
pubmed: 32302058
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
RSC Adv. 2020 Jul 28;10(47):28041-28048
pubmed: 35519100
Anal Chem. 2020 Aug 4;92(15):10196-10209
pubmed: 32573207
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
Clin Chim Acta. 2020 Aug;507:164-166
pubmed: 32343948
Pathogens. 2020 Sep 28;9(10):
pubmed: 32998438
Sensors (Basel). 2020 Dec 12;20(24):
pubmed: 33322750
Anal Chem. 2020 Jul 21;92(14):9454-9458
pubmed: 32615038
Lancet Infect Dis. 2021 May;21(5):637-646
pubmed: 33485468
Rev Sci Instrum. 2018 Feb;89(2):024103
pubmed: 29495833
ACS Nano. 2020 Oct 27;14(10):12522-12537
pubmed: 33034449
Ann Intern Med. 2021 Apr;174(4):568-570
pubmed: 33395345
Nat Commun. 2020 Nov 27;11(1):6059
pubmed: 33247099
Anal Bioanal Chem. 2008 Jul;391(5):1499-507
pubmed: 18264817
BMJ. 2021 Feb 4;372:n287
pubmed: 33541908
J Immunol Methods. 2020 Sep - Oct;484-485:112832
pubmed: 32780998
Anal Chem. 2020 Nov 3;92(21):14393-14397
pubmed: 33094615
Can J Psychiatry. 2007 Feb;52(2):121-8
pubmed: 17375868
Cell Mol Immunol. 2020 Oct;17(10):1098-1100
pubmed: 32939033
Anal Chem. 2020 Aug 18;92(16):11305-11309
pubmed: 32605363
J Clin Microbiol. 2007 Feb;45(2):600-3
pubmed: 17182758
PLoS One. 2020 Nov 23;15(11):e0241164
pubmed: 33227020
Ann Med Surg (Lond). 2020 Jun 14;56:38-42
pubmed: 32562476
Lab Chip. 2019 Aug 7;19(15):2581-2588
pubmed: 31250849
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
Lab Chip. 2020 Nov 10;20(22):4255-4261
pubmed: 33064114
J Microbiol Immunol Infect. 2020 Jun;53(3):404-412
pubmed: 32173241
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440

Auteurs

Keine Nishiyama (K)

Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, 060-8628, Japan.

Kazuki Takahashi (K)

Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, 060-8628, Japan.

Mao Fukuyama (M)

Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira 2-1-1, Aoba-ku, Sendai, 980-8577, Japan.

Motohiro Kasuya (M)

Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira 2-1-1, Aoba-ku, Sendai, 980-8577, Japan.

Ayuko Imai (A)

Tianma Japan, Ltd., Shin-Kawasaki Mitsui Building West Tower 28F 1-1-2, Kashimada, Saiwai-ku, Kawasaki, Kanagawa, 212-0058, Japan.

Takumi Usukura (T)

Tianma Japan, Ltd., Shin-Kawasaki Mitsui Building West Tower 28F 1-1-2, Kashimada, Saiwai-ku, Kawasaki, Kanagawa, 212-0058, Japan.

Nako Maishi (N)

Vascular Biology and Molecular Pathology, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7, Kita-ku, Sapporo, 060-8586, Japan.

Masatoshi Maeki (M)

Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, 060-8628, Japan.

Akihiko Ishida (A)

Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, 060-8628, Japan.

Hirofumi Tani (H)

Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, 060-8628, Japan.

Kyoko Hida (K)

Vascular Biology and Molecular Pathology, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7, Kita-ku, Sapporo, 060-8586, Japan.

Koji Shigemura (K)

Tianma Japan, Ltd., Shin-Kawasaki Mitsui Building West Tower 28F 1-1-2, Kashimada, Saiwai-ku, Kawasaki, Kanagawa, 212-0058, Japan.

Akihide Hibara (A)

Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira 2-1-1, Aoba-ku, Sendai, 980-8577, Japan.

Manabu Tokeshi (M)

Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo, 060-8628, Japan; Innovative Research Centre for Preventive Medical Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan; Institute of Innovation for Future Society, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan. Electronic address: tokeshi@eng.hokudai.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH